Commercial FITs can match NG-MSDT diagnostic results for CRC by lowering the positivity threshold, enhancing sensitivity while maintaining specificity. FITs are accessible, noninvasive CRC screening ...

In DID analysis, the rate of incidence was reduced by 0.34 cases per person-years in the screening group as compared with the historical FIT screening group (rate ratio [RR], 0.08 [95% CI, 0.07 to ...

VANCOUVER, British Columbia -- The novel multitarget stool RNA test (ColoSense) showed high sensitivity for detecting colorectal neoplasia among adults ages 45 and older, according to the phase III ...

We compared a noninvasive, multitarget stool DNA test with a fecal immunochemical test (FIT) in persons at average risk for colorectal cancer. The DNA test includes quantitative molecular assays for ...

More than 10% of fecal immunochemical tests (FIT) used for routine colorectal cancer (CRC) screening in a safety-net health system contained unsatisfactory samples that could not be processed, ...

A brief research report compared screening costs per early-detected colorectal cancer (CRC) case among fecal immunochemical tests (FIT), multitarget stool DNA tests (MSDT) and next-generation MSDTs (N ...

Please provide your email address to receive an email when new articles are posted on . Annual fecal immunochemical testing was the most effective and cheapest CRC screening method for underserved ...

Three-quarters of people prefer to do a fecal immunochemical test (FIT) rather than a colonoscopy for their regular colorectal cancer screening, according to a new Cedars-Sinai study. Unlike ...

Lindsay Curtis is a health & medical writer in South Florida. She worked as a communications professional for health nonprofits and the University of Toronto’s Faculty of Medicine and Faculty of ...